The Patent Trial and Appeal Board of the U.S. Patent and Trademark Office ruled yesterday that the claims of United Therapeutics‘s (NSDQ:UTHR) patent, which covers Remodulin, are unpatenable due to obviousness. SteadyMed (NSDQ:STDY) challenged the patent in October last year.
The patent, No. 8,497,393, relates to the process to purify prostacyclin derivatives, including treprostinil, which is the active ingredient in United’s Remodulin and SteadyMed’s Trevyent. Both candidates are designed to treat pulmonary arterial hypertension.
Get the full story at our sister site, Drug Delivery Business News.
The post More trouble for United’s Remodulin appeared first on MassDevice.
from MassDevice http://ift.tt/2oxT3ek
Cap comentari:
Publica un comentari a l'entrada